Evidence map›Paper›PMID 34391693›Full record

ArticleThe Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

Time-dependent decay of detectable antibodies against SARS-CoV-2: A comparison of ELISA with two batches of a lateral-flow test.

Mariangela F Silveira, Marilia A Mesenburg, Odir A Dellagostin, Natasha R de Oliveira, Mara Ac Maia, Francisco D Santos, André Vale, Ana M B Menezes, Gabriel D Victora, Cesar G Victora and 7 more

Abstract read
In one paragraph

Article in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mariangela F SilveiraUniversidade Federal de Pelotas, Pelotas, RS, Brazil. Electronic address: mariangelafreitassilveira@gmail.com.
Marilia A MesenburgUniversidade Federal de Pelotas, Pelotas, RS, Brazil; Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil. Electronic address: mariliaepi@gmail.com.
Odir A DellagostinUniversidade Federal de Pelotas, Pelotas, RS, Brazil. Electronic address: odird@gmail.com.
Natasha R de OliveiraUniversidade Federal de Pelotas, Pelotas, RS, Brazil. Electronic address: oliveira_natasha@hotmail.com.
Mara Ac MaiaUniversidade Federal de Pelotas, Pelotas, RS, Brazil. Electronic address: maracamaia@hotmail.com.
Francisco D SantosUniversidade Federal de Pelotas, Pelotas, RS, Brazil. Electronic address: denis.santos195@gmail.com.
André ValeUniversidade Federal do Rio de Janeiro, Rio de Janeiro,RJ, Brazil. Electronic address: valeimuno@gmail.com.
Ana M B MenezesUniversidade Federal de Pelotas, Pelotas, RS, Brazil. Electronic address: anamene.epi@gmail.com.
Gabriel D VictoraLaboratory of Lymphocyte Dynamics, Rockefeller University, New York, United States. Electronic address: victora@rockefeller.edu.
Cesar G VictoraUniversidade Federal de Pelotas, Pelotas, RS, Brazil. Electronic address: cvictora@gmail.com.
EPICOVID-19 Group
Aluisio Jd BarrosUniversidade Federal de Pelotas, Pelotas, RS, Brazil.
Luis Paulo VidalettiUniversidade Federal de Pelotas, Pelotas, RS, Brazil.
Fernando P HartwigUniversidade Federal de Pelotas, Pelotas, RS, Brazil.
Fernando C BarrosUniversidade Católica de Pelotas, Pelotas, RS, Brazil.
Pedro C HallalUniversidade Federal de Pelotas, Pelotas, RS, Brazil.
Bernardo L HortaUniversidade Federal de Pelotas, Pelotas, RS, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLarge-scale epidemiological studies of seroprevalence of antibodies against SARS-CoV-2 often rely on point-of-care tests that provide immediate results to participants. Yet, little is known on how long rapid tests remain positive after the COVID-19 episode, or how much variability exists across different brands and even among batches of the same test.

methodsIn November 2020, we assessed the sensitivity of three tests applied to 133 individuals with a previous positive PCR result between April and October. All subjects provided finger prick blood samples for two batches (A and B) of the Wondfo lateral-flow IgG/IgM test, and dried blood spot samples for the S-UFRJ ELISA test.

resultsOverall sensitivity levels were 92.5% (95% CI 86.6-96.3), 63.2% (95% CI 54.4-71.4) and 33.8% (95% CI 25.9-42.5) for the S-UFRJ test, Wondfo A and Wondfo B tests, respectively. There was no evidence of a decline in the positivity of S-UFRJ with time since the diagnosis, but the two Wondfo batches showed sharp reductions to as low as 41.9% and 19.4%, respectively, for subjects with a positive PCR in June or earlier. Positive results for batch B of the rapid test were 35% to 54% lower than for batch A at any given month of diagnosis.

interpretationWhereas the ELISA test showed high sensitivity and stability of results over the five months of the study, both batches of the rapid test showed substantial declines, with one of the batches consistently showing lower sensitivity levels than the other. ELISA tests based on dried-blood spots are an inexpensive alternative to rapid lateral-flow tests in large-scale epidemiological studies.

fundingThe study was funded by the "Todos Pela Saúde" initiative, Instituto Serrapilheira, Brazilian Ministry of Health, Brazilian Collective Health Association (ABRASCO) and the JBS S.A. initiative 'Fazer o Bem Faz Bem'.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralEnzyme-Linked Immunosorbent AssayHumansImmunoglobulin MSensitivity and SpecificitySeroepidemiologic StudiesAntibodies, ViralImmunoglobulin MELISAEpidemiological serosurveyPCRRapid testSARS-CoV-2Validation

Identifiers

PMID34391693
PMCPMC8339571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.